

KERYX BIOPHARMACEUTICALS INC  
Form 8-K  
November 04, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): November 4, 2013**

**Keryx Biopharmaceuticals, Inc.**

**(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
**(State or Other Jurisdiction**

**of Incorporation)**

**000-30929**  
**(Commission**

**File Number)**  
**750 Lexington Avenue**

**13-4087132**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: KERYX BIOPHARMACEUTICALS INC - Form 8-K

**New York, New York 10022**

**(Address of Principal Executive Offices)**

**(212) 531-5965**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act.
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

**Item 2.02. Results of Operations and Financial Condition.**

On November 4, 2013, Keryx Biopharmaceuticals, Inc. ( Keryx ) issued a press release announcing its results of operations for the third quarter ended September 30, 2013. Keryx also announced that on November 5, 2013 at 8:30am ET, Keryx will host an investor conference call to discuss Keryx s top-line results (see Item 8.01 below) at which Keryx will also briefly discuss its third quarter financial results. A copy of such press release is being furnished as Exhibit 99.1 to this report.

**Item 8.01. Other Events.**

On November 4, 2013, Keryx announced that it will host a conference call on November 5, 2013, at 8:30am ET to review the top-line results from the Phase 2 study of Zerenex (ferric citrate coordination complex), Keryx s ferric iron-based phosphate binder drug candidate, in the management of elevated serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease. A copy of such press release is being furnished as Exhibit 99.2 to this report.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.**  
(Registrant)

Date: November 4, 2013

By: /s/ James F. Oliviero  
James F. Oliviero, CFA  
Chief Financial Officer

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated November 4, 2013.
99.2	Press Release dated November 4, 2013.